Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

LYELL IMMUNOPHARMA, INC.

(LYEL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
16.05(c) 14.51(c) 13.18(c) 11.66(c) 12.09 Last
2 111 026 403 805 695 557 1 092 524 647 511 Volume
-10.58% -9.60% -9.17% -11.53% +3.69% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 10,0 M - -
Net income 2021 -268 M - -
Net cash position 2021 353 M - -
P/E ratio 2021 -7,32x
Yield 2021 -
Sales 2022 37,7 M - -
Net income 2022 -343 M - -
Net cash position 2022 216 M - -
P/E ratio 2022 -8,95x
Yield 2022 -
Capitalization 2 791 M 2 791 M -
EV / Sales 2021 243x
EV / Sales 2022 68,4x
Nbr of Employees 189
Free-Float 83,8%
More Financials
Company
Lyell Immunopharma, Inc is a T cell reprogramming company. The Company offers T cells to cure patients with solid tumors. Its technologies are designed to be applied in a target and agnostic manner to chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T cell receptor (TCR) therapies to improve the properties of T cells to eradicate solid tumors. It builds a multi-modality product pipeline... 
More about the company
All news about LYELL IMMUNOPHARMA, INC.
09/13LYELL IMMUNOPHARMA : Shares Down 19% in Late-Day Trading
MT
09/08Lyell Immunopharma to Participate in Morgan Stanley Global Healthcare Confere..
GL
08/12LYELL IMMUNOPHARMA : Management's Discussion and Analysis of Financial Condition..
AQ
08/12LYELL IMMUNOPHARMA : Reports Second Quarter 2021 Financial Results and Business ..
PU
08/12LYELL IMMUNOPHARMA, INC. : Results of Operations and Financial Condition, Financ..
AQ
08/12LYELL IMMUNOPHARMA : Earnings Flash (LYEL) LYELL IMMUNOPHARMA Reports Q2 Revenue..
MT
08/12Lyell Immunopharma Reports Second Quarter 2021 Financial Results and Business..
GL
08/12Lyell Immunopharma, Inc. Announces Unaudited Consolidated Earnings Results fo..
CI
07/12LYELL IMMUNOPHARMA : JPMorgan Starts Lyell Immunopharma at Overweight With $22 P..
MT
07/12LYELL IMMUNOPHARMA : Morgan Stanley Starts Lyell Immunopharma at Overweight With..
MT
07/12LYELL IMMUNOPHARMA : BofA Securities Starts Lyell Immunopharma at Buy With $25 P..
MT
07/12LYELL IMMUNOPHARMA : Goldman Sachs Starts Lyell Immunopharma at Buy With $30 Pri..
MT
06/17SECTOR UPDATE : Health Care Stocks Add to Afternoon Gains
MT
06/17UPDATE : Lyell Immunopharma Drops in Nasdaq Debut After IPO
MT
06/17LYELL IMMUNOPHARMA : Prices IPO at $17 Per Share
MT
More news
News in other languages on LYELL IMMUNOPHARMA, INC.

- No features available -

More news
Analyst Recommendations on LYELL IMMUNOPHARMA, INC.
More recommendations
Chart LYELL IMMUNOPHARMA, INC.
Duration : Period :
Lyell Immunopharma, Inc. Technical Analysis Chart | LYEL | US55083R1041 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 11,66 $
Average target price 25,50 $
Spread / Average Target 119%
EPS Revisions
Managers and Directors
Elizabeth Homans Chief Executive Officer & Director
Charles Newton Chief Financial Officer
Richard D. Klausner Executive Chairman
Stephen Hill Chief Technical Operations Officer
Nicholas Restifo Executive Vice President-Research
Sector and Competitors
1st jan.Capi. (M$)
LYELL IMMUNOPHARMA, INC.0.00%2 791
BIONTECH SE357.13%90 003
GILEAD SCIENCES, INC.22.43%89 434
REGENERON PHARMACEUTICALS35.20%67 910
WUXI APPTEC CO., LTD.35.75%65 728
VERTEX PHARMACEUTICALS-20.83%48 539